Online Exclusives

Online Exclusives

Disparities in Time to Treatment Erased in the Affordable Care Act Era

In states that opted to expand Medicaid under the Affordable Care Act (ACA), the time to receiving cancer treatment was nearly identical among white...

New Senate Health Package Bans “Spread Pricing” Tactics

A highly anticipated package of health care legislation from Sens. Lamar Alexander (R-TN) and Patty Murray (D-WA) that was expected to focus on surprise...

Did the Pharmaceutical Industry Influence WHO’s Pain Treatment Guidelines?

A Congressional report alleges that the World Health Organization’s (WHO’s) treatment guidelines for pain were directly influenced by opioid manufacturer Purdue Pharma. The report, stemming...

CDC: Cancer Death Rates Decline, Yet Heart Disease Deaths Rise

Rates of death from cancer in the U.S. have continued to decline, but deaths due to heart disease are on the rise, according to...

After Gene-Editing Uproar, China Poised to Adopt New Regulation

China is on the brink of adding human genes and embryos to the section of its civil code that protects personality rights, such as...

Venetoclax Approved for CLL and SLL

The U.S. Food and Drug Administration (FDA) approved venetoclax, in combination with obinutuzumab, for the treatment of adult patients with chronic lymphocytic leukemia (CLL)...

House Supports Health Care Legislation That Strengthens the Affordable Care Act

In a 234-to-183 vote, the U.S. House of Representatives passed legislation to rein in the high costs of prescription drugs and to bolster elements...

FDA’s ODAC Recommends Against Approval of Quizartinib for AML

In an 8-to-3 vote, the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drug Advisory Committee (ODAC) decided against recommending approval of quizartinib for patients...

Japan Sets $306,000 Price for Tisagenlecleucel

The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel was approved for use in Japan in March 2019, and a government panel recently set the...

Quality of Generic Drugs Manufactured Overseas Comes into Question

The passage of the Hatch-Waxman Act in 1984, which created a regulatory track for generic drugs, marked the beginning of the generic-drug boom in...
Advertisement

Current Issue

July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.